高管交接！波科心律管理与诊断业务

Core Viewpoint - Boston Scientific is undergoing a planned management transition in its Cardiac Rhythm Management & Diagnostics (CRMDx) business, with Scott Olson retiring at the end of 2025 and Angelo De Rosa taking over in early 2026 [2][3][11]. Group 1: Management Transition - Scott Olson has served as the Senior Vice President and President of the CRMDx business for 27 years and will retire at the end of 2025 [5][7]. - Angelo De Rosa, who joined Boston Scientific in 2014, will assume the role of CRMDx business leader in 2026. He has previously led the Watchman left atrial appendage closure business [8][10]. Group 2: CRMDx Business Overview - The CRMDx business focuses on cardiac rhythm management and related diagnostic solutions, including pacemakers and implantable cardioverter-defibrillators (ICDs), and is a crucial part of Boston Scientific's cardiovascular device portfolio [4]. - This business addresses core clinical needs related to arrhythmias and has a stable market foundation and strategic position within the company's overall business structure [4]. Group 3: Leadership Insights - Olson emphasized the importance of teamwork and patient-centered values during his tenure and expressed gratitude for his long-term collaboration with the internal team [7]. - De Rosa views his transition to CRMDx as a return to his roots, having previously worked in the cardiac rhythm management field early in his career [10].